Molecular Genetic Aspects of the Diagnosis of Myeloproliferative Diseases: the Example of Polycythemia Vera

Year 2021, Volume: 26 Issue: 2, 216 - 220, 29.05.2021

Svetlana Molotkova Tatyana Volk Oksana Gurevich Natalia Dekhnich Krunal Pandav

https://doi.org/10.21673/anadoluklin.818439

Abstract

Molecular genetic testing is a reliable method for the definitive diagnosis of polycythemia vera (PV). The use of interferon preparations in addition to hydroxyurea and antiplatelet agents could be associated with better therapeutic outcomes. In this report, we present the clinical case of a young patient with asymptomatic PV to demonstrate the effectiveness of molecular genetic analysis in PV diagnosis.

Keywords

janus kinase 2, myeloproliferative, polycythemia vera

Miyeloproliferatif Hastalıkların Tanısının Moleküler Genetik Yönü: Polisitemi Vera Örneği

Abstract

Moleküler genetik testler polisitemi veranın (PV) kesin teşhisi için güvenilir bir metottur. Hidroksiüre ve antiplatelet ajanlara ilaveten interferon preparatlarının kullanımı ile daha iyi terapötik sonuçlar gözlenebilir. Bu raporda, moleküler genetik testlerin PV teşhisindeki etkililiğini göstermek üzere asemptomatik PV’den muzdarip genç bir hastaya dair klinik vaka sunulmuştur.

Keywords

janus kinaz 2, miyeloproliferatif, polisitemi vera

References

• Savchenko VG. [Algorithms for Diagnosis and Treat¬ment Protocols of the Blood System Diseases], v. 2. Mos¬cow: Practice; 2018:1264.
• Melikian AL, Subortseva IN, Kovrigina AM, Koloshey¬nova TI, Abdullaev AO, Kuznetsova PI, et al. Diagnosis of latent polycythemia vera: a clinician’s opinion. Ter Arkh. 2016;88(7):25–30.
• Melikyan AL, Subortseva IN, Koloshejnova EA, Gilyazit¬dinova EA, Shashkina KS, Gorgidze LA, et al. [Clinical features and diagnosis of Ph-negative myeloproliferative neoplasms occurring in conjunction with the antiphos¬pholipid syndrome]. Ter Arkh. 2019;91(7):93–9.
• Alvarez-Larrán A, Pereira A, Cervantes F, Arellano- Rodrigo E, Hernández-Boluda JC, Ferrer-Marín F, et al. Assessment and prognostic value of the European Leu¬kemiaNet criteria for clinicohematologic response, resis¬tance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363–9.
• Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–81.
• Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.
• Vannucchi AM. How I treat polycythemia vera. Blood. 2014;124(22):3212–20.